Jazz Prices Upsized $1.1B Convertible Offering, Launches Share Buyback
JAZZ has more than doubled off its 52-week low of $122.5 on elevated volume (1.8× avg).
Summary
Jazz Pharmaceuticals priced an upsized private offering of $1.1 billion in 1.875% exchangeable senior notes due 2032, alongside concurrent ordinary share repurchases. The deal size exceeds the initially announced amount of $1.0 billion, indicating strong investor demand. The company also granted initial purchasers a 13-day option to purchase up to an additional $150.0 million of notes. The offering is expected to close on August 31. The concurrent buyback partially offsets dilution from the exchangeable notes, and the capital raise likely supports the $820 million Actio Biosciences acquisition and general corporate purposes.
At the time of this announcement, JAZZ was trading at $254.80 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $16.9B. The 52-week trading range was $122.50 to $266.38. This news item was assessed with neutral market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.